Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer withdraws sickle cell drug Oxbryta
FDA alerts patients about Pfizer's Oxbryta withdrawal
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's sickle cell disease treatment Oxbryta. Pfizer said late on Wednesday it was pulling the drug from all markets due to risk of a painful complication and death.
What the withdrawal of its sickle cell drug means for Pfizer, patients, and the FDA
Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and scrambling for ways to notify their patients about a drug that has long divided the community.
Deaths lead Pfizer to pull sickle cell drug at center of $5 billion Bay Area buyout
Pfizer had big hopes for a sickle-cell disease drug, as did those suffering from the disease. Things didn't turn out as planned.
3d
Slow progress on Pfizer's plan to sell drugs to low-income nations at not-for-profit price, says CEO
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
3d
Can Pfizer Stock Rise 2x To $60?
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
2d
Pfizer: A 6% Yielding Value Deal
Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines.
19h
Here is What Jim Cramer Likes Pfizer Inc. (NYSE:PFE)
We recently published a list of Jim Cramer’s Latest Portfolio: Top 9 Stocks to Buy and Sell. Since Pfizer Inc. (NYSE:PFE) ...
2d
Jefferies Remains a Buy on Pfizer (PFE)
Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $33.00. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Oxbryta
COVID
vaccine
New York Stock Exchange
Comirnaty
Feedback